Institut Pasteur Shanghai today signed a partnership agreement with the Griffith University’s Institute for Glycomics.
The pair will strengthen collaborative drug research and development between Australia and China, positioning themselves as leaders in drug discovery and consolidate their research capabilities in anti-infective/viral and early stage drug development.
Griffith Vice Chancellor Professor Ian O'Connor said the agreement was a significant milestone for the university. “Links with Institut Pasteur Shanghai will create unprecedented opportunities for students and researchers to shape our region’s future” Professor O’Connor said. It will draw together some of the world’s best researchers to combat the problem of infectious diseases.
The specific research focus will be the discovery and development of novel anti-viral drugs. “The world is ill-prepared to tackle existing and emerging viruses due to the lack of available drugs and vaccines,’’ Professor Mark von Itzstein, Director of the Institute for Glycomics, said.
Professor Ralf Altmeyer, Director General of Institut Pasteur Shanghai, added: “The two Institutes will take complementary advantages to collaborate in basic research and industrialisation projects with long-term vision.
“This cooperation will enable sharing of knowledge and talents, to develop drugs, vaccines and diagnostics, and continue to improve the capacity of Australia and China against infectious diseases.”
The partnership will complement the Institute for Glycomics’ existing alliances with the Institut Pasteur in Paris, Cambodia, Hong Kong and Korea.
The Institute for Glycomics was established in 2000 at the Gold Coast Campus of Griffith University.The focus of the Institute’s research is to discover the roles carbohydrates play in disease and ageing. Using this knowledge, the Institute is developing novel drugs and vaccines to interfere with the carbohydrated-related biological process of disease. This approach presents an exciting therapeutic platform for the control of a wide-range of medical conditions such as cancer, diabetes, infectious diseases, inflammation and immune disorders. The Institute is the only one of its kind in Australia and only one of six in the world. The Institute for Glycomics seeks to collaborate with leading scientists around the world to build a critical mass around carbohydrate-based research. Global collaboration together with a mutil-disciplinary approach to research, are essential to achieving our vision to bring forward novel medicines and vaccines to the community.
Institut Pasteur Shanghai, Chinese Academy of Sciences (IPS) was created in 2004 as a joint venture of the Chinese Academy of Sciences, Institut Pasteur and the Shanghai Municipal Government. IPS is an independent, non-profit life sciences institute which works to address public health issues in China. IPS creates synergies between the Institut Pasteur and CAS networks. More than 160 scientists are engaged in a broad range of infectious disease research programs ranging from Viral Hepatitis and Respiratory Viruses to virus-induced cancers.
The pair will strengthen collaborative drug research and development between Australia and China, positioning themselves as leaders in drug discovery and consolidate their research capabilities in anti-infective/viral and early stage drug development.
Griffith Vice Chancellor Professor Ian O'Connor said the agreement was a significant milestone for the university. “Links with Institut Pasteur Shanghai will create unprecedented opportunities for students and researchers to shape our region’s future” Professor O’Connor said. It will draw together some of the world’s best researchers to combat the problem of infectious diseases.
The specific research focus will be the discovery and development of novel anti-viral drugs. “The world is ill-prepared to tackle existing and emerging viruses due to the lack of available drugs and vaccines,’’ Professor Mark von Itzstein, Director of the Institute for Glycomics, said.
Professor Ralf Altmeyer, Director General of Institut Pasteur Shanghai, added: “The two Institutes will take complementary advantages to collaborate in basic research and industrialisation projects with long-term vision.
“This cooperation will enable sharing of knowledge and talents, to develop drugs, vaccines and diagnostics, and continue to improve the capacity of Australia and China against infectious diseases.”
The partnership will complement the Institute for Glycomics’ existing alliances with the Institut Pasteur in Paris, Cambodia, Hong Kong and Korea.
The Institute for Glycomics was established in 2000 at the Gold Coast Campus of Griffith University.The focus of the Institute’s research is to discover the roles carbohydrates play in disease and ageing. Using this knowledge, the Institute is developing novel drugs and vaccines to interfere with the carbohydrated-related biological process of disease. This approach presents an exciting therapeutic platform for the control of a wide-range of medical conditions such as cancer, diabetes, infectious diseases, inflammation and immune disorders. The Institute is the only one of its kind in Australia and only one of six in the world. The Institute for Glycomics seeks to collaborate with leading scientists around the world to build a critical mass around carbohydrate-based research. Global collaboration together with a mutil-disciplinary approach to research, are essential to achieving our vision to bring forward novel medicines and vaccines to the community.
Institut Pasteur Shanghai, Chinese Academy of Sciences (IPS) was created in 2004 as a joint venture of the Chinese Academy of Sciences, Institut Pasteur and the Shanghai Municipal Government. IPS is an independent, non-profit life sciences institute which works to address public health issues in China. IPS creates synergies between the Institut Pasteur and CAS networks. More than 160 scientists are engaged in a broad range of infectious disease research programs ranging from Viral Hepatitis and Respiratory Viruses to virus-induced cancers.
